Olema Pharmaceuticals (OLMA) Free Cash Flow (2020 - 2026)
Olema Pharmaceuticals (OLMA) reported Free Cash Flow of -$46.0 million for Q1 2026, down 4.57% year-over-year from -$48.2 million in Q1 2025, and down 19.99% quarter-over-quarter from -$38.3 million in Q4 2025.
Olema Pharmaceuticals (OLMA) Free Cash Flow (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has 7 years of Free Cash Flow data on file, last reported at -$46.0 million in Q1 2026.
- Free Cash Flow for Q1 2026 came in at -$46.0 million, down 4.57% year-over-year; the trailing twelve-month figure through Mar 2026 was -$148.7 million (down 19.13% YoY), and the FY2025 annual result was -$146.7 million, down 40.38% from the prior year.
- Free Cash Flow fell to -$46.0 million in Q1 2026 per OLMA's latest filing, from -$38.3 million in the prior quarter.
- Over five years, Free Cash Flow peaked at -$17.9 million in Q1 2022 and troughed at -$46.0 million in Q1 2026.
- A 5-year average of -$27.3 million and a median of -$26.3 million in 2024 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2022 and 2023: Free Cash Flow tumbled 174.52% in 2022, then advanced 16.48% in 2023.
- A 5-year view of Free Cash Flow shows it stood at -$19.9 million in 2022, then advanced by 7.08% to -$18.5 million in 2023, then slumped by 42.26% to -$26.3 million in 2024, then sank by 45.82% to -$38.3 million in 2025, then retreated by 19.99% to -$46.0 million in 2026.
- Business Quant data shows OLMA's Free Cash Flow at -$46.0 million in Q1 2026, -$38.3 million in Q4 2025, and -$34.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 63,220.27 |
| 10 | Olema Pharmaceuticals | 1.01 Bn | 1.01 Bn | - | -45.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.99 Mn |
| Mar 31, 2026 | -45.99 Mn |
| Dec 31, 2025 | -38.33 Mn |
| Dec 31, 2025 | -38.33 Mn |
| Sep 30, 2025 | -34.53 Mn |
| Sep 30, 2025 | -34.53 Mn |
| Jun 30, 2025 | -29.88 Mn |
| Jun 30, 2025 | -29.88 Mn |
| Mar 31, 2025 | -43.98 Mn |
| Mar 31, 2025 | -43.98 Mn |
| Dec 31, 2024 | -26.28 Mn |
| Dec 31, 2024 | -26.28 Mn |
| Sep 30, 2024 | -27.02 Mn |
| Sep 30, 2024 | -27.02 Mn |
| Jun 30, 2024 | -27.56 Mn |
| Jun 30, 2024 | -27.56 Mn |
| Mar 31, 2024 | -23.65 Mn |
| Mar 31, 2024 | -23.65 Mn |
| Dec 31, 2023 | -18.48 Mn |
| Dec 31, 2023 | -18.48 Mn |